The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SITC 2022 | Enhancing PD-1 blockade by inhibiting PKM2 activity in the pentose phosphate pathway
Geoffrey Markowitz, PhD, Weill Cornell Medicine, New York City, NY, discusses the role of the pentose phosphate pathway in improving the efficacy of PD-1 checkpoint inhibitors. A screen of T cells in mouse lung cancer tissue revealed cells with high levels of TCF1 expression responding more to PD-1 inhibitors, and PKM2, an enzyme involved in both glycolytic and non-glycolytic pathways, was found to influence tumor control. Ongoing studies assessing AG1, an inhibitor of PKM2, have shown promising anti-tumor effects by increasing pentose phosphate pathway activity. This interview took place at the 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC 2022) in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
